Have high blood pressure? Preventive medicine physician Dr. Ford Brewer knows two techniques that can lower it within minutes.

Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Keros Therapeutics (KROS) to $41 from $44 and keeps an Outperform rating on ...

Scotiabank (TSX:BNS) analysts revised the price target for Keros Therapeutics (NASDAQ:KROS) shares, reducing it to $41 from ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

Keros Therapeutics, Inc. has announced a voluntary halt in dosing for the Tropos trial, a phase 2 clinical trial of ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to hit a record ...

From 1999 to 2019, hyperlipidemia-related CVD mortality increased in the United States, with elderly, Black, rural men being most affected.

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...